** Shares of EyePoint Pharmaceuticals rise 36.5% to five-month high of $12.96
** Co says its drug, Duravyu, showed an improvement in how well patients can see objects at a distance in a mid-stage trial testing it in diabetic macular edema $(DME.AU)$
** DME is an eye condition that causes blurry vision in people with diabetes
** Co expects to report the full topline results in Q1 2025
** Including session's move, EYPT stock down 50.8% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。